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Factors Associated with Access to Immunotherapy and 
Its Impact on Survival in Mucosal Melanoma 
 
Joanne Jee Yeon Lee BS, Donovan Kearns BS, Medora Rodrigues MD MPH, Blake Babcock 
MD, Naveenraj Solomon MD, Maheswari Senthil MD, Mark E Reeves MD PhD, Carlos A 
Garberoglio MD, Jukes P Namm MD 
Introduction: Mucosal melanoma is rare, 
comprising only 1.4% of all melanomas in 
the United States. Yet it is associated with a 
worse prognosis compared to cutaneous 
melanoma due to aggressive biology and 
advanced stage at diagnosis with a reported 
5-year survival rate of less than 30%. 
Although there are no established guidelines 
for the treatment of mucosal melanoma, 
immunotherapy has been increasingly used 
for the management of advanced mucosal 
melanoma.  
Objective: This study aims to explore the 
trends in the early adoption of 
immunotherapy for mucosal melanoma and 
whether immunotherapy is associated with 
an overall survival (OS) benefit. 
Methods: Using the National Cancer 
Database (NCDB), patients diagnosed with 
mucosal melanoma between 2012-2014 
were identified.  Univariate and multivariate 
regression analysis were performed to 
examine factors associated with the receipt 
of immunotherapy and its effect on OS. 
Covariates included age, sex, socioeconomic 
status (SES), race, treatment facility, and 
Charlson-Deyo score. 
Results: Overall 656 patients with mucosal 
melanoma were identified, of which 86 
patients received immunotherapy. On 
multivariate analysis, younger patients (age 
<50 years) (OR 5.05, CI 95% 2.17-11.72, 
p=0.001) and patients with metastatic 
disease (OR 2.63, CI 95% 1.54-4.35, 
p<0.001) were significantly associated with 
receiving immunotherapy. Male sex (HR 
1.5, CI 95% 0.990-2.822, p=0.007) and 
treatment in an academic facility (HR 1.36, 
CI 95% 0.649-1.780, p=0.040) were 
associated with increased risk of death, 
while age<50 years  (HR 0.44, CI 95% 2.11-
11.720, p=0.011) was associated with better 
survival. Race and SES were not associated 
with the receipt of immunotherapy on 
univariate analysis (p=0.126, p=0.282 
respectively). Of the 156 patients with 
metastatic mucosal melanoma, 32 patients 
received immunotherapy with a risk-
adjusted median OS of 10.76 months. 
Patients who did not receive immunotherapy 
had a risk-adjusted median OS of 6.24 
months (p=0.745).  
Conclusion: These early data show only a 
25% adoption rate of immunotherapy for 
metastatic mucosal melanoma. Clinical 
factors such as younger age and tumor stage 
seem to influence the use of immunotherapy 
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more so than SES or race. Although male 
gender and treatment in an academic facility 
are associated with a worse prognosis, this 
may be a reflection of the extent of disease 
at presentation. The effect on survival of 
immunotherapy in metastatic mucosal 
melanoma has yet to be elucidated.   
 
 
 
 
Table. Multivariate analysis of factors associated with receiving immunotherapy 
Variable (n=656) OR C.I. (95%) p-value 
Gender     
  Female (ref male) 1.67 0.99-2.82 0.055 
Age (years)    
  < 50 (ref  >70) 5.05 2.17-11.72 0.001 
  50-70 (ref  >70 2.04 1.19-3.51 0.720 
Facility     
  Non–academic (ref 
academic) 
1.07 0.65-1.78 0.780 
Race     
  Non-white (ref white) 1.39 0.77-2.51 0.272 
Charlson-Deyo    
  ≥2 (ref 0-1) 0.24 0.04-1.64 0.145 
Metastatic disease     
  No (ref yes)  0.38 0.23-0.65 <0.001  
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